American Association for Cancer Research
19406207capr200369-sup-246979_2_supp_6626179_qhr2fm.docx (16.38 kB)

Supplementary Data 4 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians

Download (16.38 kB)
journal contribution
posted on 2023-04-03, 22:05 authored by Courtney Macdonald, Christobel M. Saunders, Louise A. Keogh, Morgan Hunter, Danielle Mazza, Sue-Anne McLachlan, Sandra C. Jones, Stephanie Nesci, Michael L. Friedlander, John L. Hopper, Jon D. Emery, Martha Hickey, Roger L. Milne, Kelly-Anne Phillips

Strongest clinician barriers to and facilitators of discussing and prescribing risk reducing medication


National Breast Cancer Foundation

Cancer Australia

Australian National Breast Cancer Foundation

and Medical Research Council

National Institute of Health USA



Guidelines endorse the use of chemoprevention for breast cancer risk reduction. This study examined the barriers and facilitators to chemoprevention use for Australian women at increased risk of breast cancer, and their clinicians. Surveys, based on the Theoretical Domains Framework, were mailed to 1,113 women at ≥16% lifetime risk of breast cancer who were enrolled in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer cohort study (kConFab), and their 524 treating clinicians. Seven hundred twenty-five women (65%) and 221 (42%) clinicians responded. Only 10 (1.4%) kConFab women had ever taken chemoprevention. Three hundred seventy-eight (52%) kConFab women, two (3%) breast surgeons, and 51 (35%) family physicians were not aware of chemoprevention. For women, the strongest barriers to chemoprevention were side effects (31%) and inadequate information (23%), which operate in the Theoretical Domains Framework domains of “beliefs about consequences” and “knowledge,” respectively. Strongest facilitators related to tamoxifen's long-term efficacy (35%, “knowledge,” “beliefs about consequences,” and “goals” domains), staying healthy for family (13%, “social role” and “goals” domains), and abnormal breast biopsy (13%, “environmental context” domain). The strongest barrier for family physicians was insufficient knowledge (45%, “knowledge” domain) and for breast surgeons was medication side effects (40%, “beliefs about consequences” domain). The strongest facilitators for both clinician groups related to clear guidelines, strong family history, and better tools to select patients (“environmental context and resources” domain). Clinician knowledge and resources, and beliefs about the side-effect consequences of chemoprevention, are key domains that could be targeted to potentially enhance uptake. Despite its efficacy in reducing breast cancer incidence, chemoprevention is underutilised. This survey study of Australian women and their clinicians used behavioural change theory to identify modifiable barriers to chemoprevention uptake, and to suggest interventions such as policy change, educational resources and public campaigns, that may increase awareness and use.See related Spotlight by Vogel, p. 1

Usage metrics

    Cancer Prevention Research



    Ref. manager